Rhonda E. Ries

EZH2-driven immune evasion at disease presentation defines atargetable high-risk subset of acute leukemia exemplified byt(16;21) FUS::ERG AML

This paper identifies an EZH2-driven immune evasion phenotype in FUS::ERG AML that is reversible with tazemetostat, offering a potential targeted therapy for high-risk acute leukemia.

DLK1 is a GATA1s-Driven Dependency and Therapeutic Target in Down Syndrome-Associated Myeloid Leukemia

This study identifies DLK1 as a GATA1s-driven dependency in Down syndrome-associated myeloid leukemia, showing it as a therapeutic target with preclinical efficacy in PDX models.

Ontogeny Dictates Oncogenic Potential, Lineage Hierarchy, and Therapy Response in Pediatric Leukemia

This study shows that the developmental stage of hematopoietic stem cells influences leukemic transformation, lineage hierarchy, and therapy response in pediatric leukemia.

TP53 Inactivation Confers Resistance to the Menin Inhibitor Revumenib in Acute Myeloid Leukemia

This study shows TP53 mutations cause resistance to revumenib in AML and suggests combining MCL-1 inhibitors with menin inhibitors could be effective.

RNAIndel: a machine-learning framework for discovery of somatic coding indels using tumor RNA-Seq data

RNAIndel identifies somatic coding indels in tumor RNA-Seq data with high sensitivity and low false positives, outperforming existing methods.